Daniel Drucker
@danieljdrucker.bsky.social
A clinician scientist at LTRI @sinaihealth studying Glucagon, GIP, GLP-1, GLP-2, diabetes, obesity, metabolism and the gut endocrine system
Pinned
Reassessment of antibody-based detection of the murine T cell GLP-1 receptor
Glucagon-like peptide 1 receptor (GLP-1R) agonists exhibit anti-inflammatory actions,
yet the importance of direct immune cell GLP-1R signaling remains uncertain. Although
T cells respond to GLP-1, lo...
www.cell.com
Our latest assessment of 3 widely used GLP-1R antisera independently with @daveyboyhod Some are useful, others not fit for purpose. Use of non-validated antisera sows confusion in the field and creates problems that are difficult to later rectify www.cell.com/cell-metabol...
The daily torrent of real world data continues. Here (lower) rates of suicidal ideation, depression and anxiety in children treated with GLP-1 medicines in Florida 🧪https://www.medrxiv.org/content/10.1101/2025.11.11.25339931v1
November 27, 2025 at 11:20 AM
The daily torrent of real world data continues. Here (lower) rates of suicidal ideation, depression and anxiety in children treated with GLP-1 medicines in Florida 🧪https://www.medrxiv.org/content/10.1101/2025.11.11.25339931v1
Rare but real. Hypophysitis www.nature.com/articles/s41... 🧪
An update on hypophysitis - Nature Reviews Endocrinology
Hypophysitis is a rare disease characterized by inflammation of the pituitary gland that can cause hypopituitarism-related symptoms, headaches and visual disturbances. This Review discusses the curren...
www.nature.com
November 27, 2025 at 11:07 AM
Rare but real. Hypophysitis www.nature.com/articles/s41... 🧪
Here the authors highlight the therapeutic potential of targeting adipocyte TGR5 for MASLD intervention 🧪https://diabetesjournals.org/diabetes/article/doi/10.2337/db25-0344/163910/Adipose-TGR5-Deletion-Promotes-Hepatic-Steatosis ada.silverchair-cdn.com/ada/content_...
November 27, 2025 at 3:11 AM
Here the authors highlight the therapeutic potential of targeting adipocyte TGR5 for MASLD intervention 🧪https://diabetesjournals.org/diabetes/article/doi/10.2337/db25-0344/163910/Adipose-TGR5-Deletion-Promotes-Hepatic-Steatosis ada.silverchair-cdn.com/ada/content_...
Here deletion of Xbp1 in β-cells (Xbp1β-/-) of non-obese diabetic mice before insulitis is protective against #diabetes
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Defining the role of β-cell IRE1α/XBP1 pathway and its gene regulatory network components in non-obese diabetic mice - Nature Communications
Modulating the unfolded protein response (UPR) can induce protective dedifferentiation of β-cells in non-obese diabetic mice. Here, the authors show that β-cell deletion of UPR transcription factor XB...
www.nature.com
November 26, 2025 at 6:37 PM
Here deletion of Xbp1 in β-cells (Xbp1β-/-) of non-obese diabetic mice before insulitis is protective against #diabetes
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Here deletion of Xbp1 in β-cells (Xbp1β-/-) of non-obese diabetic mice before insulitis is protective against #diabetes
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Defining the role of β-cell IRE1α/XBP1 pathway and its gene regulatory network components in non-obese diabetic mice - Nature Communications
Modulating the unfolded protein response (UPR) can induce protective dedifferentiation of β-cells in non-obese diabetic mice. Here, the authors show that β-cell deletion of UPR transcription factor XB...
www.nature.com
November 26, 2025 at 6:36 PM
Here deletion of Xbp1 in β-cells (Xbp1β-/-) of non-obese diabetic mice before insulitis is protective against #diabetes
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Towards a better understanding of GLP-1 medicine efficacy beyond PK-incorporation of receptor occupancy and residency time assessed in vivo www.thelancet.com/journals/ebi...
Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors
PET imaging in pigs demonstrated in vivo GLP-1R engagement by SAR441255 and tirzepatide,
and GIPR engagement by SAR441255 in the pancreas. SAR441255 exhibited dose-dependent
GLP-1R occupancy in the pa...
www.thelancet.com
November 26, 2025 at 11:38 AM
Towards a better understanding of GLP-1 medicine efficacy beyond PK-incorporation of receptor occupancy and residency time assessed in vivo www.thelancet.com/journals/ebi...
More detailed functional interrogation of enteric neuron subpopulations www.cell.com/cell/abstrac...
Properties and functions of transcriptionally distinct enteric neurons
Developing genetic access to transcriptionally distinct enteric neurons in vivo enables
the examination of morphological heterogeneity across cell types as well as cell-type-specific
influences on GI ...
www.cell.com
November 26, 2025 at 11:15 AM
More detailed functional interrogation of enteric neuron subpopulations www.cell.com/cell/abstrac...
Multiomic characterization of the aging mouse reveals fundamental insights into the aging process and identifies new therapeutic targets to maintain organ health www.cell.com/cell-metabol...
A metabolic atlas of mouse aging
Pilley et al. describe how metabolite levels change in 12 organs from male and female
mice across five ages, spanning adolescence to old age. They reveal that organs show
distinct age- and sex-specifi...
www.cell.com
November 26, 2025 at 1:39 AM
Multiomic characterization of the aging mouse reveals fundamental insights into the aging process and identifies new therapeutic targets to maintain organ health www.cell.com/cell-metabol...
A reminder that MODY (and type 1 diabetes) can present in older individuals and must remain in the differential diagnosis for new onset #diabetes across the lifespan diabetesjournals.org/diabetes/art...
MODY Is Prevalent in Later-Onset Diabetes and Has Potential for Targeted Therapy but Is Challenging to Identify
Maturity onset diabetes of the young (MODY) can present after the age of 40 years, but its prevalence and clinical characteristics, and the utility of simp
diabetesjournals.org
November 25, 2025 at 9:52 PM
A reminder that MODY (and type 1 diabetes) can present in older individuals and must remain in the differential diagnosis for new onset #diabetes across the lifespan diabetesjournals.org/diabetes/art...
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...
November 25, 2025 at 11:40 AM
New top line P2 data for Amycretin, a unimolecular agonist of the glucagon-like peptide 1 (GLP-1) and amylin receptors, intended for once-weekly subcutaneous administration and once-daily oral administration, in PPL with #T2D #weightloss
www.novonordisk.com/content/nnco...
www.novonordisk.com/content/nnco...
Beyond the bacterial #microbiome a new focus on harnessing the gut non-bacterial microbial entities in the therapeutics and prevention of metabolic diseases www.sciencedirect.com/science/arti...
November 25, 2025 at 11:29 AM
Beyond the bacterial #microbiome a new focus on harnessing the gut non-bacterial microbial entities in the therapeutics and prevention of metabolic diseases www.sciencedirect.com/science/arti...
New from Lihi Eder and colleagues-The #obesity inflammation immune axis with a focus on #psoriasis related disorders www.nature.com/articles/s41...
The obesity–inflammation axis in psoriatic disease: mechanisms and therapeutic strategies - Nature Reviews Rheumatology
This Review explores the complex relationship between obesity and psoriatic disease. The authors highlight the underlying mechanisms that drive this association and propose a comprehensive approach to...
www.nature.com
November 24, 2025 at 5:33 PM
New from Lihi Eder and colleagues-The #obesity inflammation immune axis with a focus on #psoriasis related disorders www.nature.com/articles/s41...
Oral semaglutide disappoints in the two evoke trials, failing to reduce the rate of cognitive decline #Alzheimers disease #Dementia www.novonordisk.com/content/nnco...
November 24, 2025 at 11:31 AM
Oral semaglutide disappoints in the two evoke trials, failing to reduce the rate of cognitive decline #Alzheimers disease #Dementia www.novonordisk.com/content/nnco...
On the cusp of closing the genetic association and mechanism gap while laying the foundation for future precision medicine approaches in type 2 #diabetes #genetics @diabetologiajnl.bsky.social link.springer.com/article/10.1...
Bridging the variant-to-function gap in type 2 diabetes: advances and challenges - Diabetologia
Type 2 diabetes is a polygenic, heterogeneous disease affecting over 530 million individuals worldwide, a number projected to rise to 1.3 billion by 2050. Genome-wide association studies have identifi...
link.springer.com
November 22, 2025 at 8:54 PM
On the cusp of closing the genetic association and mechanism gap while laying the foundation for future precision medicine approaches in type 2 #diabetes #genetics @diabetologiajnl.bsky.social link.springer.com/article/10.1...
P3 data for Efsubaglutide the once weekly immunoglobulin-based GLP-1 medicine approved in China for #T2D @diabetologiajnl.bsky.social link.springer.com/article/10.1...
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial - Diabetologia
Aims/hypothesis Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become an important option in clinical use for type 2 diabetes due to their dual benefits of glycaemic management and metaboli...
link.springer.com
November 22, 2025 at 8:15 PM
P3 data for Efsubaglutide the once weekly immunoglobulin-based GLP-1 medicine approved in China for #T2D @diabetologiajnl.bsky.social link.springer.com/article/10.1...
As disclosure of evoke and evoke+ trial results for oral semaglutide in people with imaging or biomarker+ #Alzheimers disease approaches, a reminder of the primary and secondary endpoints alzres.biomedcentral.com/articles/10....
November 22, 2025 at 11:46 AM
As disclosure of evoke and evoke+ trial results for oral semaglutide in people with imaging or biomarker+ #Alzheimers disease approaches, a reminder of the primary and secondary endpoints alzres.biomedcentral.com/articles/10....
Human #genetic evidence in humans is consistent with direct TAS2R38 actions in postprandial glycemia, supporting TAS2R38 as a novel therapeutic target for glucose regulation.
diabetesjournals.org/diabetes/art...
diabetesjournals.org/diabetes/art...
November 21, 2025 at 11:27 AM
Human #genetic evidence in humans is consistent with direct TAS2R38 actions in postprandial glycemia, supporting TAS2R38 as a novel therapeutic target for glucose regulation.
diabetesjournals.org/diabetes/art...
diabetesjournals.org/diabetes/art...
Towards reducing the already low risk of peri-procedural GLP-1 medicines linked aspiration. Fasting duration, rather than time since last GLP-1 dose, is a key determinant of retained gastric solid content link.springer.com/article/10.1...
November 21, 2025 at 11:22 AM
Towards reducing the already low risk of peri-procedural GLP-1 medicines linked aspiration. Fasting duration, rather than time since last GLP-1 dose, is a key determinant of retained gastric solid content link.springer.com/article/10.1...
Studies in aging male mice with extensive multi-OMICs analyses show that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment broadly counteracts age-related changes n part via the hypothalamic GLP-1R #aging www.cell.com/cell-metabol...
Body-wide multi-omic counteraction of aging with GLP-1R agonism
GLP-1R agonism counteracts body-wide aging in a brain-dependent manner, mimicking
the molecular effects of mTOR inhibition.
www.cell.com
November 21, 2025 at 1:36 AM
Studies in aging male mice with extensive multi-OMICs analyses show that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment broadly counteracts age-related changes n part via the hypothalamic GLP-1R #aging www.cell.com/cell-metabol...
Preclinical studies reveal that CCKBR-Gs and -Gq signaling, rather than CCKBR-Gi signaling, are beneficial for #Alzheimers disease (AD) treatment. www.cell.com/cell/abstrac...
Elucidating pathway-selective biased CCKBR agonism for Alzheimer’s disease treatment
Clinical evidence from AD patients reveals an association between impaired CCKBR-Gq
signaling and disease severity, guiding structure-based design of a Gq-biased agonist
that rescues memory and pathol...
www.cell.com
November 21, 2025 at 1:26 AM
Preclinical studies reveal that CCKBR-Gs and -Gq signaling, rather than CCKBR-Gi signaling, are beneficial for #Alzheimers disease (AD) treatment. www.cell.com/cell/abstrac...
A small P2 trial of 24 patients with #T1D randomized to placebo vs. Tirzepatide. Meaningful #weightloss without SAEs
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
November 20, 2025 at 10:14 PM
A small P2 trial of 24 patients with #T1D randomized to placebo vs. Tirzepatide. Meaningful #weightloss without SAEs
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
A spotlight on key concepts defining postprandial glucagon metabolism in people with and without type 1 #diabetes diabetesjournals.org/diabetes/art...
November 20, 2025 at 9:46 PM
A spotlight on key concepts defining postprandial glucagon metabolism in people with and without type 1 #diabetes diabetesjournals.org/diabetes/art...
Preclinical data suggest that GLY-200, an orally administered polymer that targets mucus and enhances barrier function, in combination with GLP-1RAs, holds promise as a
novel therapeutic strategy for #obesity www.sciencedirect.com/science/arti...
novel therapeutic strategy for #obesity www.sciencedirect.com/science/arti...
Additive Effects of GLY-200 (Oral Pharmacologic Duodenal Exclusion Therapy) and GLP-1R Agonist in Obesity Management
Type 2 diabetes and obesity impact billions of people and the global prevalence is only growing. Current treatment options, which include pharmacother…
www.sciencedirect.com
November 20, 2025 at 12:25 PM
Preclinical data suggest that GLY-200, an orally administered polymer that targets mucus and enhances barrier function, in combination with GLP-1RAs, holds promise as a
novel therapeutic strategy for #obesity www.sciencedirect.com/science/arti...
novel therapeutic strategy for #obesity www.sciencedirect.com/science/arti...
Can one target SLC25A51 the major determinant of the mitochondrial NAD+ pool to improve hepatocyte health and regeneration? www.nature.com/articles/s42...
Hepatocyte mitochondrial NAD+ content is limiting for liver regeneration - Nature Metabolism
Modulating mitochondrial NAD+ levels by changing the expression of the mitochondrial NAD+ transporter, SLC25A51, Mukherjee et al. demonstrate that mitochondrial, rather than cytosolic or nuclear, NAD+...
www.nature.com
November 20, 2025 at 12:07 PM
Can one target SLC25A51 the major determinant of the mitochondrial NAD+ pool to improve hepatocyte health and regeneration? www.nature.com/articles/s42...
Here using #genetics proxies and association with measurable GLP-1R dependent variables, the authors dismiss the non-metabolic roles of GLP1R in relevant cardiovascular tissues for GLP-1R dependent cardioprotection diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...
November 19, 2025 at 10:11 PM
Here using #genetics proxies and association with measurable GLP-1R dependent variables, the authors dismiss the non-metabolic roles of GLP1R in relevant cardiovascular tissues for GLP-1R dependent cardioprotection diabetesjournals.org/care/article... ada.silverchair-cdn.com/ada/content_...